Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):807-808.
doi: 10.1038/s41391-023-00656-4.
1 Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. Mike.Wenzel@kgu.de.
2 Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada. Mike.Wenzel@kgu.de.
3 Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.
4 Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
5 Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.
6 Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
7 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
8 Department of Urology, Weill Cornell Medical College, New York, NY, USA.
9 Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
10 Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czechia.
11 Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
12 Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
13 Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
14 Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.